APP and Alzheimer disease: The rescuing effect of fingolimod—when treatment started briefly after onset of disease symptoms—on synaptic and memory dysfunction that is accompanied by reduced microgliosis, astrogliosis and mildly reduced Aβ pathology (Kartalou et al. 2020) has meanwhile been confirmed independently by other labs, employing either a distinct APP/PS1 AD mouse model (Baloni et al. 2022), or in a combined amyloidogenic/tauopathy AD mouse model (Fagan et al. 2022).